Influence of a Lipoprotein(a)-Lowering Therapy on Insulin Sensitivity

Influence of a Lipoprotein(a)-Lowering Therapy on Insulin Sensitivity - IL(a)LTIS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031748

Enrollment

Registered

2023-05-02

Start date

2026-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E78.5

Interventions

Group 1: PCSK9-antibody therapy: Probands will receive a PCSK9-antibody therapy and will be investigated before and 8 weeks after initiation of the therapy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - dyslipidemia - initiation of PCSK-9-antibody therapy planned - age =18 years - written informed consent - sex: male or female (post-menopausal)

Exclusion criteria

Exclusion criteria: - diabetes mellitus or intake of antidiabetic drugs - pregnancy - history of thrombosis or high risk for thrombosis [cancer disease, recent surgeries (within 6 weeks), genetic thrombophilia (APC resistance, Protein S deficiency, antithrombin deficiency, Prothrombin G20210A, MTHFR gene mutation)] - pacemaker or defibrillator - intake of unknown (study) drugs

Design outcomes

Primary

Measure	Time frame
Change of insulin resistance in the muscle	—

Secondary

Measure	Time frame
- Change of insulin resistance in the liver - Change of insulin resistance in adipose tissue	—

Countries

Germany

Contacts

Public ContactDominik Soll

Charité Universitätsmedizin Berlin

dominik.soll@charite.de+49 30 450 614 219

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026